Trial Profile
Sun Yat-sen University Cancer Center
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Feb 2021
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 26 Jan 2021 Status changed from recruiting to discontinued. Reason the study was stopped:Difficulty accruing subjects the study accrual was closed
- 31 May 2020 Planned End Date changed from 1 Dec 2018 to 1 Dec 2023.
- 31 May 2020 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2022.